RT期刊文章SR电子T1年龄和复发的位置:康复多发性硬化复发的关键决定因素(S6.009)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S6.009 VO 92 15补充A1 Burcu Zeydan A1 Brittani l·康威A1 首页Ugur Uygunoglu A1玛蒂娜Novotna A1 Aksel湿婆A1肖恩·j·Pittock A1伊丽莎白·j·阿特金森A1摩西·罗德里格斯A1 Orhun h . Kantarci年2019 UL //www.ez-admanager.com/content/92/15_Supplement/S6.009.abstract AB目的:探讨年龄对复苏的影响复发的多发性硬化症时控制了一个人的内在因素。背景:不完整的复苏可能会导致增加残疾在多发性硬化复发。我们曾表明,复苏早期复发在个别病人似乎是相似的。设计/方法:第一次和最后一次复发数据(168年193例复发)以人群为基础的队列的多发性硬化症研究使用配对分析年龄的时候复发和最大康复赤字达到高峰期间复发。两个relapse-outcome措施:1)改变从高峰赤字最大恢复原始功能系统得分与复发有关(ΔFSS), 2)改变从高峰赤字规模最大扩展残疾状态复苏(ΔEDSS)得分。结果:第一个复发(年龄、平均±标准差= 30.2±8.8)和最后一次复发(年龄、平均±标准差= 45.0±10.0)相隔15年。老年与糟糕的复苏ΔFSS结果(p = 0.002)和ΔEDSS结果(p < 0.001)在一个特定的个体。ΔFSS的多变量分析结果确定之前怀疑变量;在脊髓、脑干、小脑综合症(相对于视神经炎)(p < 0.001)或复发fulminance (p = 0.004)作为附加co-variates影响经济复苏。增加脑干、小脑位置观察复发与衰老(1日复发19%;最后复发31.5%,p = 0.005)。结论:当复发从同一个人通过配对分析研究; recovery from relapses in multiple sclerosis declines with increased age, independent of relapse location, while a concomitant increase in the preponderance for brainstem/cerebellar relapses with increased age is observed. Understanding biological mechanisms underlying these observations could help future targeted drug development in multiple sclerosis.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Conway has nothing to disclose. Dr. Uygunoglu has nothing to disclose. Dr. Novotna has nothing to disclose. Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novarti Pharmaceuticals, Teva, Sanofi Genzyme, Bayer, and Roche. Dr. Pittock receives research support from Alexion Pharmaceuticals, Medimmune, and Grifols. Dr. Atkinson has nothing to disclose. Dr. Rodriguez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with MedDay. Dr. Kantarci has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharmaceuticals and Biogen. Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation.